title: Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
abstract: Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification. Its safety and efficacy were assessed in four randomized, double-blind, placebo-controlled, 56-week Phase III clinical trials in 4536 adult subjects: COR-1, COR-II, COR-BMOD and COR-DM. All four studies demonstrated statistically significant and clinically meaningful weight loss following up to 52 weeks of treatment with naltrexone/bupropion compared with placebo. The average weight loss from baseline across the four studies was approximately 11-22 lbs (5-9 kg). Results show the efficacy of Contrave for weight loss, as well as significant improvements in cardiometabolic markers. This review focuses on the four studies, their outcomes and the mechanism of action of Contrave.
authors.affiliation: Boston University School of Medicine & Boston Medical Center, Boston, MA 02118, USA.
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Apovian
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004338:Drug Combinations; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy*; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D004338:Drug Combinations; C000591595:bupropion hydrochloride, naltrexone hydrochoride drug combination; D016642:Bupropion; D009271:Naltrexone
keywords: Contrave; MC3R; MC4R; bupropion; naltrexone; obesity; opioid receptor blocker; pharmacotherapy; weight loss; α-MSH